Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115043) titled 'Multi-dimensional prediction of cardiotoxicity risk of anti-tuberculosis drugs and evaluation of the intervention effect of precise pharmaceutical services' on Dec. 22, 2025.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Ningbo First Hospital
Condition:
Drug-resistant pulmonary tuberculosis
Intervention:
Control group:Patients with drug-resistant pulmonary tuberculosis who received bedaquiline, lofazimine and moxifloxacin/levofloxacin treatment
TDM intervention group:TDM
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target...